Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-11-22
2005-11-22
Aulakh, Charanjit S. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S495000, C540S488000, C514S211070
Reexamination Certificate
active
06967198
ABSTRACT:
Protein kinase, such as CHK-1, inhibiting tricyclic compounds of the following formula (wherein R2, R3and R4are as defined in the specification)pharmaceutical compositions containing effective amounts of said compounds or their salts are useful as a single agent or in combination with an anti-neoplastic agent or therapeutic radiation having an anti-neoplastic effect for treating diseases or conditions such as cancers.
REFERENCES:
patent: 6211164 (2001-04-01), Luo et al.
patent: 6383744 (2002-05-01), Green et al.
patent: 6413755 (2002-07-01), Luyten et al.
patent: 6495541 (2002-12-01), Webber et al.
patent: 2003/0078254 (2003-04-01), Webber et al.
patent: 1096014 (2001-05-01), None
patent: WO 00/16781 (2000-03-01), None
patent: WO 00/42040 (2000-07-01), None
patent: WO 01/16136 (2001-03-01), None
patent: WO 01/16306 (2001-03-01), None
patent: WO 01/21771 (2001-03-01), None
patent: WO 02/44183 (2002-06-01), None
patent: WO 02/070494 (2002-09-01), None
Accili, D., “A Kinase In the Life of The β Cell,”Journal of Clinical Investigation,2001, pp. 1575-1576, vol. 108, No. 11.
Al-Khodairy, F., et al., “Identification And Characterization Of New Elements Involved In Checkpoint And Feedback Controls In Fission Yeast,”Molecular Biology of the Cell,1994, pp. 147-160, vol. 5.
Bagshawe, K., et. al., “Antibody-Directed Enzyme Prodrug Therapy: A Review,”Drug. Development Research,1995, pp. 220-230, vol. 34.
Barber, A., et al., “Insulin Rescues Retinal Neurons From Apoptosis By A Phosphatidylinositol 3-Kinase/Akt-Mediated Mechanism That Reduces The Activation Of Caspase-3,”Journal of Biological Chemistry,2001, pp. 32814-32821, vol. 276, No. 35.
Bartek, J., et al., “CHK2 Kinase—A busy Messenger,”Nature Reviews Molecular Cell Biology,2001, pp. 877-886, vol. 2.
Belsches, A.P., et al., “Role of C-SRC Tyrosine Kinase in EGF-Induced Mitogensis,”Frontiers in Bioscience,1997, Electronic Publication 2: D501-D518.
Bertolini, G., et. al., “A New Rational Hypothesis for the Pharmacophore of the Active Metabolite of Lefluonomide, a Potent Immunosuppressive Drug,”Journal of Med. Chem.,1997, 2011-2016, 40.
Berven, L., et al., “Cellular Function of p70S6K. A Role in Regulation Cell Motility,”Immunology and Cell Biology,2000, pp. 447-451, vol. 78, No. 4.
Bishop, A.L., et al., “Rho GTPases and Their Effector Proteins,”Biochem. J.,2000, pp. 241-255, vol. 348.
Bjorge, J., et al., “Selected Glimpses Into The Activation And Function Of Src Kinase,”Oncogene,2000, pp. 5620-5635, vol. 19, No. 49.
Blume-Jensen, P., et al., “Oncogenic Kinase Signalling,”Nature,2001, pp. 355-365, vol. 411, No. 6835.
Bodor, N., “Novel Approaches to the Design of Safer Drugs: Soft Drugs and Site-Specific Chemical Delivery Systems,”Advances in Drug Research,1984, pp. 254-331, vol. 13.
Brandon, E., et al., “PKA Isoforms, Neural Pathways, And Behaviour: Making The Connection,”Current Opinion in Neurobiology1997, pp. 397-403, vol. 7.
Brazil, D., et al., “Ten Years Of Protein Kinase B Signalling: A Hard Akt To Follow,”Trends in Biochemical Sciences,2001, pp. 657-664, vol. 26, No. 11.
Brushia, R.J., et al., “Phosphorylase Kinase: The Complexity of its regulation is Reflected in the Complexity of its Structure,”Frontiers in Bioscience(Electronic Publication), 1999, pp. D618-D641, vol. 4.
Bundgaard, H.,Design and Application of Prodrugs, Chapter 5, Drug Design Application and Development,1991, Harwood Academic Publishers.
Bundgaard, H., et al.,Design of Prodrugs,1985, Elsevier Press.
Buolamwini, J., “Cell Cycle Molecular Targets In Novel Anticancer Drug Discovery,”Current Pharmaceutical Design,2000, pp. 379-392, vol. 6.
Calautti, E., et al., “Fyn Tyrosine Kinase Is A Downstream Mediator Of Rho/PRK2 Function In Keratinocyte Cell-Cell Adhesion,”Journal of Cell Biology2002, pp. 137-148, vol. 156, No. 1.
Cannon, et al., “6-Hydroxy-4-[2-(di-n-Propylamino)ethyl]indole: Synthesis And Dopaminergic Actions,”J. Med. Chem.,1984, pp. 386-389, vol. 27.
Carter, C., “Protein Kinase C As A Drug Target: Implications For Drug Or Diet Prevention And Treatment Of Cancer,”Current Drug Targets2000, pp. 163-183, vol. 1, No. 2.
Chamoin, S., et al., “The Stille Cross Coupling Reactions On Solid Support. Link To Solution Phase Directed Ortho Metalation. An Ester Linker Approach To Styryl, Biaryl And Heterobiaryl Carboxylic Acids,”Tetrahedron Letters,1998, pp. 4175-4178, vol. 39.
Chen, Z., et al., “Map Kinases,”Chemical Reviews,2001, pp. 2449-2476, vol. 101, No. 8.
Clerk, A., et al., “Untangling The Web: Specific Signaling From PKC Isoforms To MAPK Cascades,”Circulation Research,2001, pp. 847-849, vol. 89, No. 10.
Cobb, M., et al., “Dimerization In MAP-Kinase Signaling,”Trends in Biochemical Sciences,2000, pp. 7-9, vol. 25, No. 1.
Cobb, M., et al., “How MAP Kinases Are Regulated,”Journal of Biological Chemistry,1995, pp. 14843-14846, vol. 270, No. 25.
Coe, J., et al., “Convenient Preparation Of N-Substituted Indoles By Modified Leimgruber-Batcho Indole Synthesis,”Tetrahedron Letters,1996, pp, 6045-6048, vol. 37, No. 34.
Davis, J.D., “The Mitogen-activated Protein Kinase Signal Transduction Pathway,”Journal of Biological Chemistry,pp. 14553-14556, vol. 17, No. 15.
Deak, M., et al., “Motogen- and Stress-Activated Protein Kinase-1 (MSK1) is Directly Activated by MAPK And SAPK2/p38, And May Mediate Activation Of CREB,”EMBO J.,1998, pp. 4426-4441, vol. 17, No. 15.
Deucher, A., et al., “Calcium-Dependent Involucrin Expression Is Inversely Regulated By Protein Kinase C (PKC) α And PKCδ,”Journal of Biological Chemistry,2002, pp. 17032-17040, vol. 277, No. 19.
Ellis, L., et al., “Vascular Endothelial Growth Factor In Human Colon Cancer: Biology And Therapeutic Implications,”Oncologist,2000, pp. 11-15, vol. 5 (suppl. 1).
Fagnola, M., et al., “Solid-Phase Synthesis Of Indoles Using The Palladium-Catalysed Coupling Of Alkynes With Iodoaniline Derivatives,”Tetrahedron Letters,1997, pp. 2307-2310, vol. 38, No. 13.
Fan, et al., “Cellular Effects of Olomoucine in Human Lymphoma Cells Differing in p53 function,”Chemotherapy,1999, pp. 437-445, vol. 45.
Flaggs, G., et al., Atm-dependent interactions of a mammalian Chk1 homolog with meiotic chromosomes,Current Biology,1997, pp. 977-986, vol. 7.
Frank, R., “Perspective: Potential New Medical Therapies For Diabetic Retinopathy: Protein Kinase C Inhibitors,”American Journal of Opthalmology,2002, pp. 693-698, vol. 133, No. 5.
Friedman, J., “Fat In All Wrong Places,”Nature,2002, pp. 268-269 vol. 415, No. 17.
Funder, J., “Aldosterone Action: New Answers, New Questions,”Molecular and Cellular Endocrinology,1999, pp. 1-3 vol. 151, Nos. 1-2.
Garcia-Echeverria, C., “Antagonists Of The Src Homology 2 (SH2) Domains Of Grb2, Src, Lck And ZAP-70,”Current Medicinal Chemistry,2001, pp. 1589-1604, vol. 8.
Graves, D., et al., “Substrate And Inhibitor Recognition Of Protein Kinases: What Is Known About The Catalytic Subunit Of Phosphorylase Kinase,”Pharmacol. Ther.,1999, pp. 143-155, vol. 82, Nos. 2-3.
Greenberg, S., et al., “Role Of PKC And Tyrosine Kinase In Ethanol-Mediated Inhibitor Of LPS-Inducible Nitric Oxide Synthase,”Alcohol,1998, pp. 167-175, vol. 16, No. 2.
Greene, T., et al.,Protecting Groups in Organic Synthesis,2nded., John Wiley & Sons, Inc.
Gross, C., et al., “The Protein Kinase C-Related Kinase PRK2 Interacts With The Protein Tyrosine Phosphatase PTB-BL Via A Novel PDZ Domain Binding Motif,”FEBS Letters,2001, pp. 101-104, vol. 496, Nos. 2-3.
Halpern, M., et al. “Endogenous c-src As Determinant Of The Tumorigenicity Of src Oncogenes,”Proc. Natl. Acad. Sci. USA,1996, pp. 824-827, v
Benedict Suzanne
Bennett Michael
Ninkovic Sacha
Rui Yuanjin
Teng Min
Agouron Pharmaceuticals , Inc.
Aulakh Charanjit S.
Djuardi Elsa
Hua Ye
Zielinski Bryan C.
LandOfFree
Tricyclic compounds protein kinase inhibitors for enhancing... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tricyclic compounds protein kinase inhibitors for enhancing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tricyclic compounds protein kinase inhibitors for enhancing... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3467661